Context Therapeutics CNTX

Context Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing T cell engaging bispecific antibodies for solid tumors. The company's pipeline consists of three product candidates that each combine a tumor associated antigen binding domain with a CD3 T cell engaging domain. CTIM 76 targets Claudin 6 a tight junction protein overexpressed in ovarian endometrial testicular and other solid tumors. CT 95 targets Mesothelin a membrane protein found in approximately thirty percent of cancers including ovarian pancreatic and mesothelioma. CT 202 targets Nectin 4 a cell adhesion protein frequently overexpressed in bladder colorectal lung and breast cancers. All candidates are designed to redirect T cell mediated lysis toward malignant cells expressing the respective antigen while sparing normal tissue.

Context Therapeutics Inc generates revenue primarily through upfront payments milestone payments and potential royalties from licensing and collaboration agreements. The company has received an upfront payment of $11 million from BioAtla for the worldwide license to develop manufacture and commercialize CT 202. In addition BioAtla is eligible to receive up to $122.5 million in milestone payments based on pre clinical clinical development and commercial achievements as well as tiered mid single digit to low double digit royalties on net sales. The acquisition of CT 95 from Link involved a one time payment of $3.75 million and the assumption of certain liabilities related to the transferred assets. Context Therapeutics Inc also has a collaboration and licensing agreement with Integral Molecular for the development of CTIM 76 under which Integral may receive milestone and sales payments as well as royalties on net sales of any resulting products. No product sales have been reported to date as the company remains in the clinical stage and revenue is derived solely from these partnership arrangements.

Context Therapeutics Inc competes in the fast growing field of T cell engaging bispecific antibodies for solid tumor treatment. The company differentiates itself by engineering bispecifics that retain high selectivity for their target antigens while minimizing cross reactivity with related claudin or mesothelin family members. For CTIM 76 the design emphasizes selectivity over Claudin 3 Claudin 4 and Claudin 9 which may improve safety and broaden the treatable patient population. CT 95 incorporates avidity enhancement and membrane proximal binding to counteract soluble Mesothelin fragments that can act as a decoy for conventional antibodies. CT 202 uses a pH dependent binding mechanism that favors activity in the acidic tumor microenvironment and reduces binding to Nectin 4 expressed in normal skin thereby aiming to limit dermatologic side effects. Competitors include Beigene Third Arc Bio and Xencor for Claudin 6 directed therapies Amgen for Mesothelin directed therapies and Pfizer Bicycle Therapeutics and others for Nectin 4 directed therapies. Despite the crowded landscape Context Therapeutics Inc believes its molecular engineering approach full worldwide development and commercialization rights and early clinical progress provide a competitive advantage.

The company's current customers are primarily collaboration partners contract manufacturers and clinical trial sites that support its research and development activities. Specific partners named in the filing include Integral Molecular which collaborated on the CTIM 76 program BioAtla which licensed the CT 202 asset and Link from which the CT 95 assets were acquired. Manufacturing support is provided by third party contract manufacturers such as Lonza Sales AG and Just Evotec Biologics. Clinical trial sites are located in the United States and other countries where the company conducts its Phase 1 studies for CTIM 76 CT 95 and CT 202. Eventually upon regulatory approval the company expects to serve patients hospitals oncology clinics and health care providers that treat solid tumor indications.